Cycloserine: Difference between revisions
| Line 27: | Line 27: | ||
'''| [[Cycloserine clinical studies|Clinical Studies]]''' | '''| [[Cycloserine clinical studies|Clinical Studies]]''' | ||
'''| [[Cycloserine dosage and administration|Dosage and Administration]]''' | '''| [[Cycloserine dosage and administration|Dosage and Administration]]''' | ||
'''| [[Cycloserine how supplied|How Supplied]]''' | '''| [[Cycloserine how supplied|How Supplied]]''' | ||
'''| [[Cycloserine labels and packages|Labels and Packages]]''' | '''| [[Cycloserine labels and packages|Labels and Packages]]''' | ||
Revision as of 02:01, 30 December 2013
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Chetan Lokhande, M.B.B.S [2]
Overview
Cycloserine is an oral broad spectrum antibiotic effective against tuberculosis, by inhibiting cell wall synthesis of TB bacilli at early stage of peptidoglycan synthesis. For the treatment against tuberculosis, it is classified as a second line drug.
It is also being trialed for treatment of phobias as well as an adjuvant to conventional treatments for depression, obsessive-compulsive disorder and schizophrenia.
Category
Antimycobacterial
US Brand Names
SEROMYCIN®
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Overdosage | Clinical Studies | Dosage and Administration | How Supplied | Labels and Packages